ArticleNature genetics2025
Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer.
Abstract read
In one paragraph
Article in Nature genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Stemness in Colon Cancer.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Article
- Cell plasticity in cancer and therapy resistance.Experimental & molecular medicine · 2026Review
- Single-cell epigenomics of colorectal cancer.Experimental & molecular medicine · 2026Review
- Review
- Resolving cell-cell interaction networks and their molecular logic in complex tissues.Nature methods · 2026Article
- CpG hypermethylation and WNT/AP-1 cooperativity define the epigenetic landscape and a clinical subgroup of high-risk pediatric adrenocortical carcinoma.Nature communications · 2026Article
- A single-cell lens into the co-evolution of genotypes and phenotypes in cancer.Nature reviews. Cancer · 2026Review
- Article
- Cystic Fibrosis and Colorectal Cancer Risk: Reprogramming of the Intestinal Epithelial Niche and Cell-State Plasticity in the CFTR Modulator Era.Cell proliferation · 2026Review
- Lineage plasticity driven by GATA6 loss fuels colorectal cancer metastasis.Cell stem cell · 2026Article
- Article
- Molecular subtyping of adrenocortical carcinoma reveals distinct subtypes with prognostic and therapeutic implications.Endocrine-related cancer · 2026Article
- Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer.Cancer cell · 2026Article
- Progressive intestinal tumor cell plasticity, Myc activation, and loss of Lgr5Science advances · 2026Article
- Developmental timing distinguishes pediatric and adult cancers through retention and rewiring mechanisms.Nature communications · 2026Review
- Testican-1 activates Wnt/β-Catenin signaling to drive colorectal cancer progression.Oncogenesis · 2026Article
- Dynamic Reprogramming of PDGFRA-Expressing Stromal Cells Facilitates WNT-Driven Transformation by Promoting a Fetal-Like State in the Intestinal Epithelium.Cancer research · 2026Article
- LGR5: from stem cell marker to therapeutic target.Trends in cancer · 2026Review
- Article
Corrections and comments
- Update of
Authors and funding
26 authors.
Slim MzoughiCenter for OncoGenomics and Innovative Therapeutics (COGIT), Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. slim.mzoughi@mssm.edu.ORCID http://orcid.org/0000-0002-5158-0389
Megan Schwarz *Center for OncoGenomics and Innovative Therapeutics (COGIT), Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Xuedi Wang *Tisch Cancer Institute Bioinformatics for Next Generation (BiNGS) Sequencing Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0009-0000-7238-745X
Deniz Demircioglu *Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-7857-0407
Gulay UlukayaTisch Cancer Institute Bioinformatics for Next Generation (BiNGS) Sequencing Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kevin MohammedCenter for OncoGenomics and Innovative Therapeutics (COGIT), Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-9955-9407
Habiba ZorgatiCenter for OncoGenomics and Innovative Therapeutics (COGIT), Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-9840-7156
Denis TorreCenter for OncoGenomics and Innovative Therapeutics (COGIT), Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4615-223X
Lewis E TomalinTisch Cancer Institute Bioinformatics for Next Generation (BiNGS) Sequencing Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4545-7138
Federico Di TullioDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Carlos CompanyMax Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany.
Yuliia DramaretskaMax Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany.ORCID http://orcid.org/0000-0002-9792-0465
Marc LeushackeInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Bruno GiottiDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tamsin Rm LannaganCancer Research UK, Scotland Institute, Glasgow, UK.ORCID http://orcid.org/0000-0002-8206-8898
Daniel Lozano-OjalvoDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-3524-2929
Panagiotis KarrasLaboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, Leuven, Belgium.ORCID http://orcid.org/0000-0002-7642-0875
Peter B VermeulenTranslational Cancer Research Unit, Ziekenhuis aan de Stroom (ZAS), Antwerp, Belgium.
Dan HassonDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Robert SebraDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-9267-2426
Alexander M TsankovDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-7955-4414
Owen J SansomCancer Research UK, Scotland Institute, Glasgow, UK.ORCID http://orcid.org/0000-0001-9540-3010
Jean-Christophe MarineLaboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, Leuven, Belgium.ORCID http://orcid.org/0000-0003-2433-9837
Nick BarkerInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.ORCID http://orcid.org/0000-0003-3566-4475
Gaetano GargiuloMax Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany.ORCID http://orcid.org/0000-0001-5414-4251
Ernesto GuccioneCenter for OncoGenomics and Innovative Therapeutics (COGIT), Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ernesto.guccione@mssm.edu.ORCID http://orcid.org/0000-0001-7764-5307
Funding
Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4MTHE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MTranslational Immunology Training ProgramT32AI078892 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Karen Leigh Edelblum, SERGIO A. LIRA · 2008 to 2026
$4.5MFunctional and molecular characterization of Oncofetal Stem Cells in CRCR01CA292376 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Slim Mzoughi · 2024 to 2026
$2.8MCOVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0MBig Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0MNCATS NIH HHS UL1 TR004419NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA292376NIAID NIH HHS T32 AI078892NIH HHS S10 OD026880NIH HHS S10 OD030463Wellcome Trust
Abstract
Targeting cancer stem cells (CSCs) is crucial for effective cancer treatment, yet resistance mechanisms to LGR5
Indexed as
Cellular ReprogrammingColorectal NeoplasmsNeoplastic Stem CellsAnimalsCell PlasticityDrug Resistance, NeoplasmFemaleFluorouracilHumansMicePhenotypeReceptors, G-Protein-CoupledWnt Signaling PathwayFluorouracilLGR5 protein, humanReceptors, G-Protein-Coupled
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.